Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682382 · ClinicalTrials.gov registry record
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 45
- Enrollment target
NCT01682382 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 45 participants.
The verdict
NCT01682382 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to wet AMD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682382
The ClinicalTrials.gov registry entry for NCT01682382 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01682382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682382 about?
NCT01682382 is a clinical study titled "Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)". Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to ...
What is the current status of trial NCT01682382?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2012-08. Estimated completion is 2013-10.
Who is sponsoring clinical trial NCT01682382?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.